Partnervest Advisory Services LLC Grows Position in Johnson & Johnson (JNJ)

Partnervest Advisory Services LLC lifted its holdings in Johnson & Johnson (NYSE:JNJ) by 6.5% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 7,021 shares of the company’s stock after acquiring an additional 428 shares during the period. Partnervest Advisory Services LLC’s holdings in Johnson & Johnson were worth $970,000 as of its most recent filing with the SEC.

Other hedge funds have also added to or reduced their stakes in the company. Selective Wealth Management acquired a new stake in Johnson & Johnson during the third quarter worth about $105,000. WP Advisors LLC acquired a new stake in Johnson & Johnson during the second quarter worth about $108,000. Fusion Family Wealth LLC grew its stake in Johnson & Johnson by 621.4% during the second quarter. Fusion Family Wealth LLC now owns 1,010 shares of the company’s stock worth $123,000 after buying an additional 870 shares in the last quarter. Cognios Beta Neutral Large Cap Fund LP acquired a new stake in Johnson & Johnson during the second quarter worth about $203,000. Finally, Exane Asset Management acquired a new stake in Johnson & Johnson during the second quarter worth about $206,000. Institutional investors and hedge funds own 68.98% of the company’s stock.

A number of equities research analysts have issued reports on JNJ shares. Raymond James increased their price objective on shares of Johnson & Johnson from $144.00 to $149.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 17th. Credit Suisse Group increased their price objective on shares of Johnson & Johnson from $149.00 to $152.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 17th. Zacks Investment Research downgraded shares of Johnson & Johnson from a “hold” rating to a “sell” rating in a research note on Wednesday, January 16th. Citigroup dropped their target price on shares of Johnson & Johnson from $148.00 to $139.00 and set a “neutral” rating for the company in a report on Wednesday, January 2nd. Finally, ValuEngine raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Thursday, December 13th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and eight have given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $142.20.

In related news, CAO Ronald A. Kapusta sold 3,643 shares of the firm’s stock in a transaction that occurred on Thursday, December 13th. The shares were sold at an average price of $147.31, for a total value of $536,650.33. Following the completion of the transaction, the chief accounting officer now owns 13,641 shares in the company, valued at approximately $2,009,455.71. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Charles Prince acquired 2,000 shares of the company’s stock in a transaction that occurred on Friday, December 14th. The stock was acquired at an average price of $134.37 per share, with a total value of $268,740.00. Following the acquisition, the director now owns 28,520 shares in the company, valued at $3,832,232.40. The disclosure for this purchase can be found here. In the last quarter, insiders sold 465,746 shares of company stock valued at $67,951,916. 0.22% of the stock is owned by company insiders.

JNJ stock opened at $132.40 on Monday. The stock has a market capitalization of $355.22 billion, a PE ratio of 16.19, a P/E/G ratio of 2.11 and a beta of 0.68. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.72 and a quick ratio of 1.40. Johnson & Johnson has a 12 month low of $118.62 and a 12 month high of $148.99.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, January 22nd. The company reported $1.97 EPS for the quarter, topping analysts’ consensus estimates of $1.95 by $0.02. The firm had revenue of $20.39 billion during the quarter, compared to analysts’ expectations of $20.27 billion. Johnson & Johnson had a net margin of 18.75% and a return on equity of 35.09%. The business’s revenue for the quarter was up 1.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.74 earnings per share. As a group, analysts anticipate that Johnson & Johnson will post 8.57 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 12th. Investors of record on Tuesday, February 26th will be issued a $0.90 dividend. The ex-dividend date is Monday, February 25th. This represents a $3.60 dividend on an annualized basis and a yield of 2.72%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 44.01%.

Johnson & Johnson declared that its Board of Directors has initiated a share repurchase plan on Monday, December 17th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the company to buy up to 1.5% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s board of directors believes its shares are undervalued.

TRADEMARK VIOLATION WARNING: “Partnervest Advisory Services LLC Grows Position in Johnson & Johnson (JNJ)” was first reported by WKRB News and is owned by of WKRB News. If you are reading this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The original version of this piece of content can be accessed at https://www.wkrb13.com/2019/02/11/partnervest-advisory-services-llc-grows-position-in-johnson-johnson-jnj.html.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Read More: How to read a candlestick chart

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply